A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

BACKGROUND: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs...

Descripción completa

Detalles Bibliográficos
Autores principales: LeCaer, H, Barlesi, F, Corre, R, Jullian, H, Bota, S, Falchero, L, Vergnenegre, A, Dujon, C, Delhoume, J Y, Chouaid, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208485/
https://www.ncbi.nlm.nih.gov/pubmed/21934690
http://dx.doi.org/10.1038/bjc.2011.331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208485/
https://www.ncbi.nlm.nih.gov/pubmed/21934690
http://dx.doi.org/10.1038/bjc.2011.331

Ejemplares similares